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Introduction
Ovarian hyperstimulation syndrome (OHSS) results from
an exaggerated response to ovulation induction, character-
ized by a fluid shift from the intravascular space to third
space compartments. The incidence of moderate OHSS is
approximately 3–6% and severe OHSS occurs in 0.1–3% of
treatment cycles [1, 2]. A number of causal mechanisms
have been investigated, involving estradiol (E2), human
chorionic gonadotropin (hCG), and vascular endothelial
growth factor (VEGF). A strong association between E2
concentrations and risk for developing OHSS has been
observed consistently [3].
A growing awareness and interest in treatments aimed at
fertility preservation (FP) has led many women to pursue
urgent oocyte or embryo cryopreservation. Those with
estrogen-sensitive cancers often receive adjunctive treat-
ment with letrozole, in efforts to limit exposure to elevated
estrogen concentrations that typically result from exoge-
nous gonadotropin stimulation; letrozole inhibits estrogen
production by binding competitively to the cytochrome
P450 component of the aromatase enzyme. Combination
stimulation regimens yield results comparable to those
achieved with standard gonadotropin stimulation protocols,
but are associated with significantly lower E2 levels [4].
The risk of OHSS for women receiving adjunctive
treatment with letrozole generally is considered low,
because E2 levels are markedly lower than in cycles
stimulated with gonadotropins alone. In fact, no cases of
severe OHSS have been reported in a patient receiving
combined treatment with letrozole and gonadotropins.
Here, we report a case of severe OHSS arising in a woman
with breast cancer after stimulation with exogenous
gonadotropins, despite treatment with letrozole and having
only moderately elevated E2 concentrations.
Case report
A 35-year-old G3P1021 with a recent diagnosis of
breast cancer underwent FP consultation. She had an
established pattern of irregular menses, but had con-
ceived previously without medical assistance and deliv-
ered a healthy child. Two subsequent pregnancies ended
in miscarriages. Recent treatment with clomiphene
citrate succeeded in inducing ovulation, but failed to
achieve pregnancy. After discovering a lump in her right
breast, a biopsy of the 1.8 cm mass revealed a breast
cancer that was positive for both estrogen and proges-
terone receptors. Her prescribed treatment included
mastectomy and adjuvant chemotherapy with adriamycin
and cisplatin. Her BMI was 19.3 kg/m2 and she had mild
hirsutism. Transvaginal ultrasonography demonstrated
multicystic ovaries. Her anti-mullerian hormone (AMH)
concentration was 12.0 ng/mL. The patient chose to
pursue urgent IVF and embryo cryopreservation after
breast surgery, before receiving chemotherapy.
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A unilateral mastectomy was performed, and subse-
quently, the patient received treatment with letrozole
(Femara, Novartis, 5 mg daily) beginning on cycle day 2,
followed by recombinant follicle-stimulating hormone
(Gonal F, Serono Inc., Rockland, MA; 225 IU daily) 2 days
later (day 4) [4]. Cetrorelix (Cetrotide, Serono Inc., Rock-
land, MA) was started when the lead follicle reached
14 mm (day 10). Recombinant hCG (Ovidrel 250 μg,
Serono Inc., Rockland, MA) was administered on day 14
when the lead follicles reached 20 mm, 22 follicles were
14–20 mm, 2 were 10–14 mm, and the E2 was 636 pg/mL
(Table 1). Two days later, 40 oocytes were retrieved; 28
mature oocytes received intra-cytoplasmic sperm injection
(ICSI) and 19/28 (68%) fertilized, ultimately yielding 9
embryos for cryopreservation. Treatment with letrozole was
continued.
On day 19, the patient complained of abdominal
bloating; the E2 was 99 pg/mL. On day 22 she presented
with abdominal distension and respiratory discomfort; her
E2 was 177 pg/mL, her hematocrit was 43.1%, and no
electrolyte abnormalities were evident. Her weight was
101 lb (99 lb at baseline) and an abdominal fluid wave was
demonstrable. Transvaginal ultrasound revealed markedly
enlarged ovaries (8×8 cm, bilaterally) and significant free
fluid; paracentesis removed 1.5 l. The patient was admitted
to the hospital and treatment with cabergoline 0.5 mg/day
was initiated. She was discharged on day 23 but returned
with recurrent symptoms 1 day later, when a second
transvaginal paracentesis removed 900 ml of fluid, resolv-
ing her symptoms. On day 29, the E2 concentration was
45 pg/mL and treatment with both letrozole and cabergoline
was discontinued. Her planned regimen of chemotherapy
began on day 27.
Discussion
This is the first report describing a case of severe OHSS
arising in a patient receiving adjunctive treatment with
letrozole during gonadotropin stimulation for IVF. Whereas
the peak E2 was only 636 pg/mL, she exhibited features of
polycystic ovary syndrome (irregular menses, multicystic
ovaries, and a relatively high serum AMH) and had a
relatively low BMI, both recognized as independent risk
factors for OHSS [5]. Our case illustrates that severe OHSS
can develop in patients with risk factors, even when E2
levels are not grossly elevated.
High circulating E2 levels are strongly associated with
OHSS. The American Society of Reproductive Medicine
(ASRM) recommends caution when E2 levels are rising
rapidly or exceed 2,500 pg/mL [5]. However, in cycles
involving adjunctive treatment with letrozole, serum E2
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anovulatory women have demonstrated that letrozole can
induce ovulation and is associated with lower peak E2
levels than with other methods of ovulation induction [6,
7]. Because E2 levels rise only modestly during treatment
with gonadotropins and letrozole, it might be assumed that
risk for developing OHSS is low. Although this patient
developed severe OHSS despite treatment with letrozole,
the clinical course of this patient may have been worse if
she had not been on letrozole. In a study involving 74
patients receiving stimulation with letrozole and gonado-
tropins for FP, 11/74 (15%) developed mild-moderate
OHSS [8], but none developed severe illness.
High concentrations of E2 alone are unlikely to cause
OHSS unless hCG also is elevated [9]. The use of hCG to
promote the final stages of oocyte maturation in
gonadotropin-stimulated cycles is another factor contribut-
ing to risk for developing OHSS. A retrospective study of
cycles stimulated by combined treatment with letrozole and
gonadotropins wherein final oocyte maturation was
achieved by treatment with hCG or a GnRH agonist
(GnRHa, leuprolide acetate) found that GnRHa treatment
was followed by a significant decrease in serum E2 levels
and a lower incidence of OHSS [8]. This retrospective
study demonstrated that OHSS can occur after stimulation
with letrozole and gonadotropins and that use of GnRHa
can mitigate the risk of its development.
We report a case of severe OHSS arising in a cycle
involving combined treatment with letrozole and gonado-
tropins despite a relatively low peak E2. Our observations
may help to raise awareness of the risk for OHSS in such
cycles, particularly in patients having other known risks
factors, including young age, a low BMI, and polycystic
ovary syndrome. Available evidence suggests that in
antagonist cycles, treatment with GnRHa, instead of hCG
should be considered when the risk of OHSS is increased. It
is important to minimize risk of OHSS in patients receiving
urgent FP treatment because prolonged exposure to
elevated E2 is best avoided, the disorder can be more
serious in patients already in poor health, and severe illness
can delay cancer treatment.
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